Serina Therapeutics (NYSEAMERICAN:SER) Stock Rating Upgraded by BTIG Research

Serina Therapeutics (NYSEAMERICAN:SER) was upgraded by investment analysts at BTIG Research to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Serina Therapeutics Price Performance

NYSEAMERICAN SER opened at $1.90 on Wednesday. The firm has a market cap of $28.50 million, a P/E ratio of -0.95 and a beta of 1.11. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.18 and a current ratio of 4.18. The firm has a 50-day moving average price of $1.84. Serina Therapeutics has a 1-year low of $1.22 and a 1-year high of $7.92.

Serina Therapeutics (NYSEAMERICAN:SER) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share (EPS) for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.